Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...

New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...

In this study, researchers aimed to determine whether patients with standard-risk relapsed/refractory multiple myeloma had improved survival with earlier-line cilta-cel therapy.

The FDA has “proactively” granted Johnson & Johnson a coveted speedy review under the Commissioner’s National Priority ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have uncovered biological differences ...

From 2017 to 2024, newly diagnosed multiple myeloma (MM) patients rapidly received quadruplet therapies over triplets, with ...

In the phase 3 COBRA trial, the carfilzomib/lenalidomide/dexamethasone regimen shows significant improvements in PFS and ...

Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...

Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving clinical data—highlighting the shift toward a comprehensive, multi-phase approach ...

Legend Biotech Corp (NASDAQ:LEGN) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, ...

If you have multiple myeloma, your chances of surviving it are better than ever. But people of different races, genders, socioeconomic levels, and ages often don’t get equal care. They also don't have ...